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2It is with great pleasure that we announce the launch of a new
ournal dedicated to tuberculosis and other mycobacterial diseases.
Tuberculosis (TB) remains a major global health problem. In 2013,
n estimated 9.0 million people developed TB and 1.5 million died
rom the disease. Tuberculosis is the second leading cause of death
rom an infectious disease worldwide, after the human immunodeﬁ-
iency virus infection. While there has been progress in the efforts to
ontrol tuberculosis, considerablework remains to be done to achieve
he Millennium Development Goals of reducing the global burden of
uberculosis. There has been a resurgence of interest among scientists
nd commercial companies in investigating how tuberculosis causes
isease and acquires resistance to drugs; there is interest in devel-
ping new diagnostic methods, vaccines, and therapeutics as well.
ore than 50 companies are involved in development of new diag-
ostic tests. At least 10 new or repurposed TB drugs are in late phases
f clinical development. There are 10 vaccines for TB prevention and
immunotherapeutic vaccines in the pipeline.
Determining the global burden of non-tuberculous (NTM) my-
obacterial infections is diﬃcult because reporting these infections
o public health departments is not required. Nevertheless, published
eports indicate that non-tuberculous mycobacterial infections are
ncreasing. The treatment of these infections is more problematic
han many people realize. Many NTM organisms are resistant to cur-
ently available antibiotics and require a longer course of treatment
han tuberculosis. The cost associatedwithmanaging these infections
ay be several fold than that of tuberculosis.
In spite of the disease burden represented by tuberculosis and
ther mycobacterial diseases, there is a lack of a venue/platform
or a robust and focused exchange of clinical experiences and ev-
dence basis for managing these diseases. While there are opin-
ons and guidance provided on various issues by a number of enti-
ies, these are either published on websites and/or provided through
rochures/monographs, often lacking the rigor of a peer-reviewed
nd duly-processed article. At present, there are only a handful of
nglish-language medical journals that have tuberculosis as a pri-
ary focus; one is focused on basic science research, the remainders
ave a broad focus that includes other lung diseases, such as asthma,
cute respiratory infection, COPD, child lung health, tobacco, and pol-
ution, in addition to tuberculosis. There is no medical journal thatttp://dx.doi.org/10.1016/j.jctube.2015.07.001
405-5794/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article undeas non-tuberculous mycobacteria as its primary focus. Articles on
ycobacteria are distributed over a broad range of journals, demon-
trating the lack of focus on these topics. In 2013, there were 3818
rticles with their title containing the word “tuberculosis”. Of these
rticles, 222 were in 33 journals that are designated as core clini-
al journals. Similarly, there were 186 articles in 2013 with their title
ontaining the word “mycobacteria”. These articles were distributed
mong 113 journals.
We believe that the Journal of Clinical Tuberculosis and Other my-
obacterial Diseases (JCTUBE) ﬁlls an unmet need by providing a plat-
orm for the dissemination of results of clinically relevant research;
he sharing of clinical observations that illustrate important points,
ighlight complexities, generate discussions, and provide impetus for
urther clinical research; and the presentation of expert opinion on
opics for which clinical trial-based evidence to direct clinical man-
gement is not available. Thus, it is very appropriate that the launch of
his journal is announced onWorld TB day, a day that commemorates
he date in 1882 when Robert Koch delivered his presentation an-
ouncing the discovery of Mycobacterium tuberculosis before a group
f scientists at the Physiological Society in Berlin.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
JCTUBE) is a Gold Open Access journal published by Elsevier and is
dited by leading international experts in the ﬁeld. We look forward
o your submissions, comments, and active participation. Let’s start
ublishing!
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